Hurthle Cell Carcinoma

  • Elgin Özkan
  • Çiğdem Soydal


Hurthle cell carcinoma (HCC) is a histopathologic variant of follicular thyroid carcinoma. HCC is more aggressive than follicular tumors. It causes more nodal metastases than follicular cancer, and it has the highest metastatic frequency among the differentiated thyroid cancers. In this report, we describe a 50-year-old female patient who presented with an enlarging palpable mass in the left thyroid lobe for 3 years. Neck ultrasonography (USG) demonstrated a 4 × 2.5 × 4 cm heterogeneous isoechoic nodule in the left thyroid lobe. There was no pathologic lymph node on USG. The patient underwent a left hemithyroidectomy, and histopathological examination of the surgical specimen revealed a Hurthle cell carcinoma with a maximum diameter of 4.2 cm. Radioiodine ablation treatment (RAT) with 3700 MBq (100 mCi) iodine-131 (131I) was applied approximately 2 months after the operation. Six months after the RAT, diagnostic whole-body scintigraphy with 185 MBq (5 mCi) 131I was performed. The serum-stimulated Tg level and the 131I whole-body scintigraphy were entirely normal. There has been no evidence of disease, on the 8-year follow-up period. Despite of good response to therapy, due to high risk of HCC, the patient is still under close follow-up.


Hurthle cell carcinoma Differentiated thyroid cancer Follicular cell carcinoma 


  1. 1.
    Masood S, Auguste LJ, Westerband A, Belluco C, Valderama E, Attie J. Differential oncogenic expression in thyroid follicular and Hürthle cell carcinomas. Am J Surg. 1993;166:366–8.CrossRefGoogle Scholar
  2. 2.
    McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J. Hürthle cell carcinoma: prognostic factors and results of surgical treatment. Surgery. 1996;120:1000–4.CrossRefGoogle Scholar
  3. 3.
    De Lellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs in WHO classification of tumours. 1st ed. Lyon: World Health Organization; 2004.Google Scholar
  4. 4.
    Ahmed M, Bin Yousef H, Greer W, Faraz H, Al Sobhi S, Al Zahrani A, et al. Hurthle cell neoplasm of the thyroid gland. ANZ J Surg. 2008;78:139–43.CrossRefGoogle Scholar
  5. 5.
    Mills SC, Haq M, Smellie WJ, Harmer C. Hurthle cell carcinoma of the thyroid: retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol. 2009;35:230–4.CrossRefGoogle Scholar
  6. 6.
    Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83:2638–48.CrossRefGoogle Scholar
  7. 7.
    Haigh PI, Urbach DR. The treatment and prognosis of Hurthle cell follicular thyroid carcinoma compared with its non-Hurthle cell counterpart. Surgery. 2005;138:1152–7.CrossRefGoogle Scholar
  8. 8.
    Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery. 1995;118:1131–6.CrossRefGoogle Scholar
  9. 9.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;26:1–133.CrossRefGoogle Scholar
  10. 10.
    Jillard C, Youngwirth L, Scheri R, Roman S, Sosa JA. Radioactive iodine treatment is associated with improved survival for patients with hurthle cell carcinoma. Thyroid. 2016;26:959–64.CrossRefGoogle Scholar
  11. 11.
    Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ. Clinical safety and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid. 2013;23:392–407.CrossRefGoogle Scholar
  12. 12.
    Spano JP, Vano Y, Vignot S, De La Motte RT, Hassani L, Mouawad R, et al. GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Med Oncol. 2012;29:1421–8.CrossRefGoogle Scholar
  13. 13.
    Foote RL, Brown PD, Garces YI, Mclver B, Kasperbauer JL. Is there a role for radiation therapy in the management of Hurthle cell carcinoma? Int J Radiat Oncol Biol Phys. 2003;56:1067–72.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Elgin Özkan
    • 1
  • Çiğdem Soydal
    • 2
  1. 1.Department of Nuclear MedicineMedical Faculty of Ankara UniversityAnkaraTurkey
  2. 2.Department of Nuclear MedicineAnkara University School of MedicineAnkaraTurkey

Personalised recommendations